CTRC-AACR San Antonio Breast Cancer Symposium
The 2011 CTRC-AACR San Antonio Breast Cancer Symposium was presented in December by the Cancer Therapy & Research Center at University of Texas Health Science Center at San Antonio, the American Association for Cancer Research, and Baylor College of Medicine. The driving force behind this collaboration is the shared mission of the organizations to advance progress in breast cancer research.
Highlights from the research presented include:
- Diabetes and Obesity Increase Risk for Breast Cancer Development
- Molecular Differences May Be Used to Predict Early vs. Late Hormone Receptor-Positive Breast Cancer Recurrence
- Brachytherapy Was Associated with Twofold Increased Risk for Mastectomy, Complications
- Zoledronic Acid Shows Long-Term Benefit in Survivorship for Premenopausal ER-Positive Breast Cancer
- Clodronate Appeared Safe, Modestly Affected Breast Cancer Disease Events
- Immediate Bisphosphonate Use with Endocrine Therapy Reduced Recurrence, Increased Survival in Postmenopausal Early Breast Cancer
- Dual HER2 Blockade Significantly Extends Progression-Free Survival
- Exemestane Plus Everolimus Increased Progression-Free Survival for Women with Metastatic Breast Cancer
- Addition of Bevacizumab to Conventional Therapy Improved Progression-Free Survival in HER2- Positive Breast Cancer
- Bilateral Oophorectomy Associated with Higher Prevalence of Low Bone Mineral Density and Arthritis in Younger Women
- Addition of Trastuzumab May Potentially Equalize Disease-Free Survival Outcomes Among Obese and Normal-Weight Patients
- MRI May be Noninvasive Method to Measure Breast Cancer Prognosis
♦ ♦ ♦ ♦ ♦
For more information on these studies, visit sabcs.org.
This article was originally published in Coping® with Cancer magazine, January/February 2012.